Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04191577 · ClinicalTrials.gov registry record · Phase 2
Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase 2 study, sponsored by Cerevance Beta.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT04191577: Completed Phase 2 study, sponsored by Cerevance Beta.
NCT04191577 is a Phase 2 study that has completed, run by Cerevance Beta. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04191577, a Phase 2 study, has completed, sponsored by Cerevance Beta.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
Primary Outcome
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAEs are defined as any event with onset during or after the first dose of study treatment (active or placebo).
Interventions
- DRUG Placebo
- DRUG CVN424 Low Dose
- DRUG CVN424 High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 2 |
What the finished NCT04191577 record still lists
NCT04191577 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04191577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04191577 about?
NCT04191577 is a clinical study titled "Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations". This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
What is the current status of trial NCT04191577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2019-12-02. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT04191577?
The interventions under investigation include: Placebo (DRUG), CVN424 Low Dose (DRUG), CVN424 High Dose (DRUG).
Who is sponsoring clinical trial NCT04191577?
This trial is sponsored by Cerevance Beta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04191577's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI